Durvalumab with gemcitabine-cisplatin neoadjuvant treatment and durvalumab adjuvant treatment for muscle-invasive bladder cancer

Neoadjuvant treatment of durvalumab in combination with gemcitabine-cisplatin and adjuvant treatment of durvalumab alone are currently in clinical development for patients with muscle-invasive bladder cancer (MIBC). Bladder cancer is where a growth of abnormal tissue, known as a tumour, develops in the bladder lining. When the cancerous cells spread beyond the lining, into the surrounding bladder muscle, it is referred to as MIBC. However, limited treatment options exist for patients with MIBC.